Tirzepatide
GIP GLP-1 co-agonist / Mounjaro / Zepbound
- Peptide length
- 39 amino acids
Acylated peptide analog
Open the sources to check how the studies were done and what they can support.
A dual GIP and GLP-1 receptor agonist used in regulated medicines with product-specific indications.
- Family
- Dual incretin agonist
- Research target
- GIP and GLP-1 receptors
- Molecular form
- Acylated peptide analog
- Formula reported by the source
- C225H348N48O68
What to know about the research
Distinguish diabetes, weight-management and obstructive-sleep-apnea evidence. Receptor activity alone does not predict comparative clinical outcomes.
Check the exact compound
Check the full modified structure and lipid side chain. A backbone length or purity percentage does not establish pharmaceutical equivalence.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries